NCT00265551View on ClinicalTrials.gov

Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

PHASE2CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

January 31, 2006

Study Completion Date

January 31, 2007

Conditions

Schizophrenia

Interventions

DRUG

SCA-136 (200 mg)

DRUG

SCA-136 (400 mg)

DRUG

olanzapine (15 mg)

DRUG

placebo

Trial Locations (35)

11423

Holliswood

11516

Cedarhurst

19034

Fort Washington

20016

Washington D.C.

20850

Rockville

21202

Baltimore

33161

North Miami

33301

Fort Lauderdale

34741

Kissimmee

38117

Memphis

44022

Chagrin Falls

45220

Cincinnati

45267

Cincinnati

46222

Indianapolis

60194

Hoffman Estates

63118

St Louis

70601

Lake Charles

72201

Little Rock

73103

Oklahoma City

75115

DeSoto

78729

Austin

78756

Austin

90502

Torrance

90660

Pico Rivera

90703

Cerritos

90723

Paramount

91770

Rosemead

91942

La Mesa

92056

Oceanside

92103

San Diego

92123

San Diego

92627

Costa Mesa

98493

Tacoma

06457

Middletown

08046

Willingboro

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00265551 - Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia | Biotech Hunter | Biotech Hunter